FI3576740T3 - Syöpähoito - Google Patents
Syöpähoito Download PDFInfo
- Publication number
- FI3576740T3 FI3576740T3 FIEP18702299.1T FI18702299T FI3576740T3 FI 3576740 T3 FI3576740 T3 FI 3576740T3 FI 18702299 T FI18702299 T FI 18702299T FI 3576740 T3 FI3576740 T3 FI 3576740T3
- Authority
- FI
- Finland
- Prior art keywords
- erdafitinib
- use according
- cancer
- fgfr3
- phosphate levels
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Prostheses (AREA)
- Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
- Laminated Bodies (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455211P | 2017-02-06 | 2017-02-06 | |
| EP17209098 | 2017-12-20 | ||
| PCT/EP2018/052694 WO2018141921A1 (en) | 2017-02-06 | 2018-02-02 | Cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3576740T3 true FI3576740T3 (fi) | 2023-08-31 |
Family
ID=61094531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18702299.1T FI3576740T3 (fi) | 2017-02-06 | 2018-02-02 | Syöpähoito |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11077106B2 (enExample) |
| EP (2) | EP4286005A3 (enExample) |
| JP (3) | JP2020505425A (enExample) |
| KR (2) | KR20190110581A (enExample) |
| CN (1) | CN110198716A (enExample) |
| AU (2) | AU2018216969B2 (enExample) |
| BR (1) | BR112019016043A2 (enExample) |
| CA (1) | CA3049737A1 (enExample) |
| DK (1) | DK3576740T3 (enExample) |
| ES (1) | ES2953005T3 (enExample) |
| FI (1) | FI3576740T3 (enExample) |
| HR (1) | HRP20230697T1 (enExample) |
| HU (1) | HUE062453T2 (enExample) |
| IL (1) | IL268463A (enExample) |
| JO (1) | JOP20190190A1 (enExample) |
| LT (1) | LT3576740T (enExample) |
| MX (2) | MX2019009304A (enExample) |
| PH (1) | PH12019501885A1 (enExample) |
| PL (1) | PL3576740T3 (enExample) |
| RS (1) | RS64778B1 (enExample) |
| SG (2) | SG10202105110VA (enExample) |
| SI (1) | SI3576740T1 (enExample) |
| SM (1) | SMT202300233T1 (enExample) |
| TW (1) | TWI874925B (enExample) |
| UA (1) | UA126336C2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200208224A1 (en) * | 2014-09-26 | 2020-07-02 | Janssen Pharmaceutica Nv | Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor |
| SMT202200177T1 (it) | 2014-09-26 | 2022-05-12 | Janssen Pharmaceutica Nv | Uso di gruppi di geni mutanti del fgfr nell'identificazione di pazienti affetti da cancro che saranno responsivi al trattamento con un inibitore del fgfr |
| JOP20190190A1 (ar) * | 2017-02-06 | 2019-08-04 | Janssen Pharmaceutica Nv | معالجة سرطان |
| MA54932A (fr) * | 2019-02-12 | 2021-12-22 | Janssen Pharmaceutica Nv | Traitement contre le cancer |
| WO2020205493A1 (en) * | 2019-03-29 | 2020-10-08 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| EP3946340A1 (en) * | 2019-03-29 | 2022-02-09 | Janssen Pharmaceutica NV | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| AU2021220285A1 (en) * | 2020-02-12 | 2022-10-06 | Janssen Pharmaceutica Nv | FGFR tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
| WO2021201201A1 (ja) * | 2020-04-03 | 2021-10-07 | インタープロテイン株式会社 | 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物 |
| TW202508591A (zh) * | 2023-05-24 | 2025-03-01 | 比利時商健生藥品公司 | 癌症治療 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) * | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| JOP20190190A1 (ar) * | 2017-02-06 | 2019-08-04 | Janssen Pharmaceutica Nv | معالجة سرطان |
-
2017
- 2017-06-16 JO JOP/2019/0190A patent/JOP20190190A1/ar unknown
-
2018
- 2018-02-02 US US16/483,579 patent/US11077106B2/en active Active
- 2018-02-02 AU AU2018216969A patent/AU2018216969B2/en active Active
- 2018-02-02 PL PL18702299.1T patent/PL3576740T3/pl unknown
- 2018-02-02 KR KR1020197024552A patent/KR20190110581A/ko not_active Ceased
- 2018-02-02 LT LTEPPCT/EP2018/052694T patent/LT3576740T/lt unknown
- 2018-02-02 FI FIEP18702299.1T patent/FI3576740T3/fi active
- 2018-02-02 ES ES18702299T patent/ES2953005T3/es active Active
- 2018-02-02 SG SG10202105110VA patent/SG10202105110VA/en unknown
- 2018-02-02 DK DK18702299.1T patent/DK3576740T3/da active
- 2018-02-02 BR BR112019016043-4A patent/BR112019016043A2/pt not_active Application Discontinuation
- 2018-02-02 SI SI201830961T patent/SI3576740T1/sl unknown
- 2018-02-02 SG SG11201907199QA patent/SG11201907199QA/en unknown
- 2018-02-02 EP EP23178682.3A patent/EP4286005A3/en active Pending
- 2018-02-02 UA UAA201909567A patent/UA126336C2/uk unknown
- 2018-02-02 KR KR1020257014703A patent/KR20250069693A/ko active Pending
- 2018-02-02 HU HUE18702299A patent/HUE062453T2/hu unknown
- 2018-02-02 EP EP18702299.1A patent/EP3576740B1/en active Active
- 2018-02-02 CN CN201880008126.XA patent/CN110198716A/zh active Pending
- 2018-02-02 TW TW112109467A patent/TWI874925B/zh active
- 2018-02-02 HR HRP20230697TT patent/HRP20230697T1/hr unknown
- 2018-02-02 JP JP2019541398A patent/JP2020505425A/ja not_active Withdrawn
- 2018-02-02 CA CA3049737A patent/CA3049737A1/en active Pending
- 2018-02-02 SM SM20230233T patent/SMT202300233T1/it unknown
- 2018-02-02 RS RS20230615A patent/RS64778B1/sr unknown
- 2018-02-02 MX MX2019009304A patent/MX2019009304A/es unknown
-
2019
- 2019-08-04 IL IL268463A patent/IL268463A/en unknown
- 2019-08-05 MX MX2022007955A patent/MX2022007955A/es unknown
- 2019-08-05 PH PH12019501885A patent/PH12019501885A1/en unknown
-
2021
- 2021-06-28 US US17/360,618 patent/US20220110935A1/en not_active Abandoned
-
2022
- 2022-11-28 JP JP2022189239A patent/JP7668777B2/ja active Active
-
2024
- 2024-03-22 AU AU2024201871A patent/AU2024201871A1/en active Pending
- 2024-11-11 JP JP2024196985A patent/JP2025024064A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3576740T3 (fi) | Syöpähoito | |
| Huang et al. | CDK4/6 inhibitor resistance mechanisms and treatment strategies | |
| Zhang et al. | Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine | |
| Shiah et al. | Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma | |
| Mahipal et al. | FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma | |
| Karthigeyan et al. | Biology of Aurora A kinase: implications in cancer manifestation and therapy | |
| Zhang et al. | PI3K/Akt signaling in osteosarcoma | |
| Sun et al. | Small molecule inhibitors in pancreatic cancer | |
| Hescot et al. | Pancreatic atrophy—a new late toxic effect of sorafenib | |
| Kornmann et al. | Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer | |
| JP2020505425A5 (enExample) | ||
| HRP20191145T1 (hr) | Postupak predviđanja ishoda liječenja s afliberceptom kod pacijenta za kojeg se sumnja da ima rak | |
| Soheilifar et al. | Molecular landscape in alveolar soft part sarcoma: implications for molecular targeted therapy | |
| Pivonello et al. | The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma | |
| Kurihara-Hosokawa et al. | Epithelioid inflammatory myofibroblastic sarcoma responsive to surgery and an ALK inhibitor in a patient with panhypopituitarism | |
| Kollmannsberger | Sunitinib side effects as surrogate biomarkers of efficacy | |
| Cheng et al. | Management of imatinib‐related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour | |
| Di Paolo et al. | Simultaneous, but not consecutive, combination with folinate salts potentiates 5-fluorouracil antitumor activity in vitro and in vivo | |
| Moguillansky et al. | Bosutinib induced pleural effusions: case report and review of tyrosine kinase inhibitors induced pulmonary toxicity | |
| BR112020016073A2 (pt) | Métodos e terapia de combinação para tratar câncer do trato biliar | |
| Iannone et al. | Recovery of barium swallow radiographic abnormalities in a patient with dermatomyositis and severe dysphagia after high-dose intravenous immunoglobulins | |
| Imperiale et al. | Metabolic response to BRAF-MEK combination therapy in cecal neuroendocrine carcinoma with BRAFV600E mutation and refractory lactic acidosis | |
| ZA202203668B (en) | Methods of treating antipsychotic-induced weight gain with miricorilant | |
| Karaca et al. | Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature | |
| CN103864784A (zh) | 一种新型氮杂吲哚-2-酮类fgfr1抑制剂及其抗肿瘤活性 |